BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the...
...Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals...
...rare disease products at Novartis' oncology China unit. Jonathan Block, Associate Editor and Hongjiang Li, Staff Writer CASI Pharmaceuticals Inc. Black...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...Staff Writers Keytruda, pembrolizumab (MK-3475, lambrolizumab) Livalo, Livazo, pitavastatin (NK-104) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) AstraZeneca plc Be The Match BioTherapies CASI Pharmaceuticals Inc. Chia...
BioCentury | Jun 19, 2019
Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

...to its autologous anti-CD19 T cell therapy CNCT19 for B cell driven hematological malignancies to CASI Pharmaceuticals Inc....
...undisclosed milestones and royalties and will receive an RMB80 million ($11.5 million) equity investment from CASI Pharmaceuticals...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...senior director of market access and reimbursement at Biogen Inc. (NASDAQ:BIIB). Cancer and generics company CASI Pharmaceuticals Inc....
...He was CFO of Quanterix Corp. (NASDAQ:QTRX). BioCentury Staff Agios Pharmaceuticals Inc. Arvinas Bio-Rad Laboratories Inc. Biohaven Pharmaceutical Holding Co. Ltd. CASI Pharmaceuticals Inc. Centogene...
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...was EVP and chief strategy officer at Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Cancer and generics company CASI Pharmaceuticals Inc....
BioCentury | Sep 28, 2018
Company News

Management tracks: Zai, Selecta

...hired Adam Mostafa as CFO. He was CFO at Abpro Corp. (Woburn, Mass.). Cancer company CASI Pharmaceuticals Inc....
BioCentury | Apr 13, 2018
Clinical News

China advisory committee to review CASI's multiple myeloma therapy

...on April 6. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: Evomela melphalan (IV Captisol-enabled Melphalan) Business: Transplant Sandi Wong Evomela CASI Pharmaceuticals Inc....
BioCentury | Mar 23, 2018
Financial News

CASI raises $50M in private placement

...Cancer company CASI Pharmaceuticals Inc. (NASDAQ:CASI) raised $50 million on March 20 in a private placement through the...
...of Pharmacyclics Inc., which AbbVie Inc. (NYSE:ABBV) acquired in 2015. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Elizabeth S. Eaton CASI Pharmaceuticals Inc....
BioCentury | Oct 27, 2017
Financial News

CASI raises $23.9M in registered direct offering

...On Oct. 13, CASI Pharmaceuticals Inc. (NASDAQ:CASI) raised $23.9 million through the sale of 8 million units at...
...China, including Hong Kong and Macau, from Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI). CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Jennie Walters CASI Pharmaceuticals Inc....
BioCentury | Jun 2, 2017
Clinical News

CASI completes enrollment in Phase II of ENMD-2076 for TNBC

...In April, CASI Pharmaceuticals Inc. (NASDAQ:CASI) completed enrollment of 41 patients in a Phase II trial of ENMD-2076...
...CBR). ENMD-2076 is an inhibitor of aurora kinase A (AURKA; Aurora-A) and multiple tyrosine kinases. CASI Pharmaceuticals Inc....
...breast cancer (TNBC) Endpoint: Clinical benefit rate (CBR) Status: Completed Phase II enrollment Milestone: NA Alex Himes ENMD-2076 CASI Pharmaceuticals Inc. Aurora...
Items per page:
1 - 10 of 429
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the...
...Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals...
...rare disease products at Novartis' oncology China unit. Jonathan Block, Associate Editor and Hongjiang Li, Staff Writer CASI Pharmaceuticals Inc. Black...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...Staff Writers Keytruda, pembrolizumab (MK-3475, lambrolizumab) Livalo, Livazo, pitavastatin (NK-104) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) AstraZeneca plc Be The Match BioTherapies CASI Pharmaceuticals Inc. Chia...
BioCentury | Jun 19, 2019
Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

...to its autologous anti-CD19 T cell therapy CNCT19 for B cell driven hematological malignancies to CASI Pharmaceuticals Inc....
...undisclosed milestones and royalties and will receive an RMB80 million ($11.5 million) equity investment from CASI Pharmaceuticals...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...senior director of market access and reimbursement at Biogen Inc. (NASDAQ:BIIB). Cancer and generics company CASI Pharmaceuticals Inc....
...He was CFO of Quanterix Corp. (NASDAQ:QTRX). BioCentury Staff Agios Pharmaceuticals Inc. Arvinas Bio-Rad Laboratories Inc. Biohaven Pharmaceutical Holding Co. Ltd. CASI Pharmaceuticals Inc. Centogene...
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...was EVP and chief strategy officer at Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Cancer and generics company CASI Pharmaceuticals Inc....
BioCentury | Sep 28, 2018
Company News

Management tracks: Zai, Selecta

...hired Adam Mostafa as CFO. He was CFO at Abpro Corp. (Woburn, Mass.). Cancer company CASI Pharmaceuticals Inc....
BioCentury | Apr 13, 2018
Clinical News

China advisory committee to review CASI's multiple myeloma therapy

...on April 6. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: Evomela melphalan (IV Captisol-enabled Melphalan) Business: Transplant Sandi Wong Evomela CASI Pharmaceuticals Inc....
BioCentury | Mar 23, 2018
Financial News

CASI raises $50M in private placement

...Cancer company CASI Pharmaceuticals Inc. (NASDAQ:CASI) raised $50 million on March 20 in a private placement through the...
...of Pharmacyclics Inc., which AbbVie Inc. (NYSE:ABBV) acquired in 2015. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Elizabeth S. Eaton CASI Pharmaceuticals Inc....
BioCentury | Oct 27, 2017
Financial News

CASI raises $23.9M in registered direct offering

...On Oct. 13, CASI Pharmaceuticals Inc. (NASDAQ:CASI) raised $23.9 million through the sale of 8 million units at...
...China, including Hong Kong and Macau, from Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI). CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Jennie Walters CASI Pharmaceuticals Inc....
BioCentury | Jun 2, 2017
Clinical News

CASI completes enrollment in Phase II of ENMD-2076 for TNBC

...In April, CASI Pharmaceuticals Inc. (NASDAQ:CASI) completed enrollment of 41 patients in a Phase II trial of ENMD-2076...
...CBR). ENMD-2076 is an inhibitor of aurora kinase A (AURKA; Aurora-A) and multiple tyrosine kinases. CASI Pharmaceuticals Inc....
...breast cancer (TNBC) Endpoint: Clinical benefit rate (CBR) Status: Completed Phase II enrollment Milestone: NA Alex Himes ENMD-2076 CASI Pharmaceuticals Inc. Aurora...
Items per page:
1 - 10 of 429